Croda expands biopharma capabilities through strategic partnership

PRESS RELEASE

19 November 2025: Croda International Plc (“Croda”), a global leader in specialty ingredients, today announced a strategic supply partnership with Amino GmbH (“Amino”), a leading manufacturer of pharmaceutical-grade amino acids, aimed at strengthening the global availability of high purity amino acids for pharmaceutical formulation and biomanufacturing.

Combining Croda’s deep expertise in smart science and global market reach, with Amino’s advanced capabilities in precision manufacturing of amino acids will enable Croda to deliver even more innovative, high-quality and sustainable solutions  that help customers accelerate their product development and achieve greater efficiency.

"This partnership reflects Croda’s strategy, to strengthen our ability to support customers in the fast-evolving biopharma landscape” said Katie Dec, Global Business Director, Croda International Plc. "Amino’s strong reputation and expertise  make them an ideal partner as we continue to deliver high-quality, reliable materials needed to bring new therapies to market.” 

“The partnership with Croda is both a milestone and a catalyst for Amino’s ambitions in biopharmaceuticals. The combination of Croda’s market reach and our high-purity amino acid production expertise forms a partnership dedicated to meeting specific customer demands,” states Lutz Thomas, Managing Director of Amino GmbH.

This reinforces Croda’s commitment to supplying the highest purity ingredients for pharmaceutical formulation and biomanufacturing and follows on from the recent launches of Virodex™ for viral inactivation and cell lysis, and Super Refined  ™ Poloxamer 188 as a shear protectant in cell culture media.

For more information on our latest products: Croda Pharma | Super Refined Polaxamer 188